PR Newswire BiotechOriginal article
AQUAPASS Completes Enrollment in REFORM-HF Pivotal Trial, Results to Be Presented at Major Heart Failure Conference This Fall
Phase 3AQUAPASS therapyPositive
AI Analysis
Summary
AQUAPASS announced completion of enrollment in the REFORM-HF pivotal trial for its noninvasive kidney-independent fluid overload management therapy in heart failure patients. Results are expected to be presented at a major heart failure conference in fall 2026.
Clinical Trial Data
Phase
3
Outcome Details
Enrollment completed in REFORM-HF pivotal trial; results to be presented at major heart failure conference in fall 2026
Importance:6/10
Sentiment:
0.60
heart failurekidney diseasepivotal trialenrollment completionnoninvasive therapy
Read the original article
Published by PR Newswire Biotech on August 10, 2026 1:40 PM